ClinicalTrials.gg
CompletedNCT02055157ACHUpdated Jan 15, 2021Results posted

A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

A Phase 2 interventional study of BMN 111 in Achondroplasia, sponsored by BioMarin Pharmaceutical. Completed at 9 sites in 4 countries. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
5 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Achondroplasia by BioMarin Pharmaceutical — 2 open to participants now, 6 under way, 2 of them phase 3. Achondroplasia · BioMarin Pharmaceutical.

Enrollment
8th of 10
35 · median 74
Started
2014
the only one that year
Phase 2
5 of 14
none open now
Registered
3rd of 14
by date

Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2014, is one of 5 in phase 2, and was the 3rd registered.

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

Browse Achondroplasia studies →

Open to participants now

2 of the 14 studies in Achondroplasia by BioMarin Pharmaceutical are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 5 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Achondroplasia by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.

03

Conditions studied

  • Achondroplasia

Keywords

  • Achondroplasia
  • Dwarfism
  • Bone Diseases, Developmental
  • Bone Diseases
04

Who can participate

Ages eligible
5 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parent(s) or guardian(s) are willing and able to provide written, signed
  • 5 to 14 years old at end of study
  • ACH, documented by clinical grounds, confirmed by genetic testing
  • At least 6-month of pretreatment growth assessment in Study 111-901 before study entry, and one standing height at least 6 months prior to screening for 111-202
  • Negative pregnancy test at the Screening Visit for females ≥ 10 years old or who have begun menses
  • If sexually active, willing to use a highly effective method of while participating in the study
  • Ambulatory, able to stand without assistance
  • Willing and able to perform all study procedures as physically possible
  • Parents/caregivers willing to administer daily injections to the subjects

Additional inclusion Criteria Optional, Open-label Extension Phase:

  • Appropriate written informed consent

Exclusion criteria

Exclusion Criteria:

  • Hypochondroplasia or short stature condition other than ACH
  • Have any of the following:

    • Hypothyroidism or hyperthyroidism
    • Insulin-requiring diabetes mellitus
    • inflammatory disease
    • Inflammatory bowel disease
    • Autonomic neuropathy
    • Recent acute illness associated with volume dehydration not completely resolved prior to the first dose of study drug
  • Unstable condition requiring surgical intervention during the study
  • Growth plates have fused
  • Have a history of any of the following:

    • Renal insufficiency, defined as creatinine > 2 mg/dl
    • Anemia
    • Baseline systolic BP \< 75 mm Hg or recurrent symptomatic hypotension or recurrent symptomatic hypotension, recurrent symptomatic orthostatic hypotension
    • Cardiac or vascular disease, including the following:

      • Cardiac dysfunction (abnormal echocardiogram [ECHO] including left ventricle [LV] mass) at Screening Visit
      • Hypertrophic cardiomyopathy
      • Pulmonary Hypertension
      • Congenital heart disease with ongoing cardiac dysfunction
      • Cerebrovascular disease
      • Aortic insufficiency
      • atrial or ventricular arrhythmias
  • Have an showing any of the following:

    • Right or left atrial enlargement or ventricular hypertrophy
    • PR (period of time from the beginning of atrial depolarization until the beginning of ventricular depolarization) interval > 200 msec
    • QRS (The Q, R, and S heart waves that are measured on an electrocardiogram) interval > 110 msec
    • Corrected -F (Measure of the corrected time between the start of the Q wave and end of the T wave in the heart's electrical cycle) > 450 msec
    • Second- or third-degree atrioventricular block
  • Documented Vitamin D deficiency
  • Require any agent prior to completion of study period
  • Have received another investigational product or investigational medical device within 30 days before the Screening visit
  • Use of any other investigational product or investigational medical device for the treatment of ACH or short stature
  • Current chronic therapy with antihypertensive medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac glycosides, systemic anticholinergic agents, any medication that may impair or enhance compensatory tachycardia, diuretics, or other drugs known to alter renal or tubular function
  • Treatment with growth hormone, IGF-1 (Insulin-like growth factor), or anabolic steroids in the previous 6 months or long-term treatment (> 3 months) at any time
  • Long-term treatment (> 1 month) with oral
  • Concomitant medication that prolongs the QT/QTc-F interval within 14 days or 5 half-lives, whichever is longer, before the Screening visit
  • Pregnant or breastfeeding at the Screening Visit or planning to become pregnant (self or partner) at any time during the study
  • Limb-lengthening or bone-related surgery \< 18 months prior to study enrollment
  • Had a fracture of the long bones or spine within 6 months prior to screening (except for fracture of digits or toes)
  • (Aspartate Transaminase) or ALT (Alanine Transaminase) at least 3x (ULN) or total at least 2x ULN
  • Evidence of severe sleep apnea requiring surgery or new initiation of CPAP (Continuous positive airway pressure).
  • History of and chemotherapy/radiation or currently under work-up for suspected malignancy
  • Known to BMN 111 or its
  • Have a condition or circumstance that, in the view of the Investigator, places the subject at high risk for poor treatment compliance or for not completing the study
  • Concurrent disease or condition that would interfere with study participation or safety
  • Have abnormal findings on baseline clinical hip exam or imaging assessments that are determined to be clinically significant as determined by the PI.
  • Have a history of hip surgery or severe hip dysplasia
  • Have a history of clinically significant hip injury in the 30 days prior to screening.
  • History of slipped capital femoral epiphysis or avascular necrosis of the femoral head.
  • Are unable to lie flat when in prone position

Additional Exclusion Criteria for Optional, Open-label Extension Phase:

  • Use of restricted therapies during the initial 6 months of the study
  • Permanently discontinued BMN 111 during the initial 6 months of the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Cohort 1: 2.5 ug/kg

    Drug: BMN 111

  • Experimental
    Cohort 2

    Cohort 2: 7.5 ug/kg,

    Drug: BMN 111

  • Experimental
    Cohort 3

    Cohort 3: 15 ug/Kg

    Drug: BMN 111

  • Experimental
    Cohort 4

    Cohort 4: 30 ug/kg

    Drug: BMN 111

Interventions

  • BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.

    Also known as: Modified recombinant human C-type natriuretic peptide, Vosoritide

06

What researchers measure

Primary outcomes

  1. Overall Summary of Adverse Events During Initial 6-Month Period

    A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. Serious adverse event (SAE).

    Time frame: Up to Month 6 ± 7 Days

  2. Overall Summary of Adverse Events During Entire Study Period

    A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. TEAE - Treatment-emergent adverse event. SAE - Serious adverse event.

    Time frame: Up to Month 25 ± 7 Days

Secondary outcomes

  1. Change From Baseline in Annualized Growth Velocity (AGV) During Initial 6-Month

    Annualized Growth Velocity at Day 183 is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.

    Time frame: At 6 month (Day 183)

  2. Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 3 and 4

    Annualized Growth Velocity at Day 183 visit is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.

    Time frame: At month 24

  3. Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 1 and 2 Switchers

    Annualized Growth Velocity at 1st visit with \>= 12 months on 15ug/kg is assessed on standing height as ((Height at 1st Visit with \>= 12 Months on 15 μg/kg - Height at 1st Visit on 15 μg/kg)/(Date of the 1st Visit with \>= 12 months on 15 μg/kg - Date of at 1st Visit on 15 μg/kg)) x 365.25.

    Time frame: At month 24

  4. Change From Baseline in Height Z-Scores Using Centers for Disease Control and Prevention (CDC) Reference Standard During Initial 6-Months

    Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 Standard Deviation Scores (SDs) indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).

    Time frame: At month 6 (Day 183)

  5. Change From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 3 and 4

    Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 SDs indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).

    Time frame: At month 24

  6. Change From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 1 and 2 Switchers

    Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 SDs indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).

    Time frame: At month 24

  7. Change From Baseline in Upper to Lower Body Ratios During Initial 6-Months

    The Upper to Lower Body ratio prior to treatment, at baseline, and through 6 months is assessed on Sitting Height / (Standing Height - Sitting Height)

    Time frame: At month 6 (Day 183)

  8. Change From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 3 and 4

    The Upper to Lower Body ratio prior to treatment, at baseline, and through 24 months is assessed on Sitting Height / (Standing Height - Sitting Height)

    Time frame: At month 24

  9. Change From Baseline in Upper Arm Length to Lower Arm (Forearm) Length Ratio During Initial 6-Months

    The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 6 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.

    Time frame: At month 6 (Day 183)

  10. Change From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 3 and 4

    The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 24 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.

    Time frame: At month 24

  11. Change From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 1 and 2 Switchers

    The Upper to Lower Body ratio prior to treatment, at baseline, and through 24 months is assessed on Sitting Height / (Standing Height - Sitting Height)

    Time frame: At month 24

  12. Change From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers

    The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 24 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.

    Time frame: At month 24

  13. Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Initial 6-months

    The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 6 months is assessed on Upper Leg Length (Thigh) / Knee to Heel Length.

    Time frame: At month 6 (Day 183)

  14. Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 3 and 4

    The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh) / Knee to Heel Length.

    Time frame: At month 24

  15. Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers

    The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh) / Knee to Heel Length.

    Time frame: At month 24

  16. Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Initial 6-months

    The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 6 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.

    Time frame: At month 6 (Day 183)

  17. Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 3 and 4

    The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.

    Time frame: At month 24

  18. Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers

    The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.

    Time frame: At month 24

  19. Change From Baseline in Arm Span to Height Ratio During Initial 6-months

    The Arm Span to Height Ratio prior to treatment, at baseline, and through 6 months is assessed by Arm Span / Standing Height.

    Time frame: At month 6 (Day 183)

  20. Change From Baseline in Arm Span to Height Ratio During Entire Study Period - Cohort 3 and 4

    The Arm Span to Height Ratio prior to treatment, at baseline, and through 24 months is assessed by Arm Span / Standing Height.

    Time frame: At month 24

  21. Change From Baseline in Arm Span to Height Ratio During Entire Study Period - Cohort 1 and 2 Switchers

    The Arm Span to Height Ratio prior to treatment, at baseline, and through 24 months is assessed by Arm Span / Standing Height. Values are not available for participants in cohort 1 switchers for Change from Baseline to \>=12 Months on 15ug/kg.

    Time frame: At month 24

07

Results

Posted Jan 15, 2021

Participant flow

This study was conducted at nine study centers in United States, Australia, United Kingdom and France.

Initial 6 Months
Participant flow — Initial 6 Months
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started88109
Completed77108
Not completed1101
Withdrew: Subject discontinued due to needlephobia0100
Withdrew: Adverse event0001
Withdrew: Consent withdrawn by subject1000
18-month Extension
Participant flow — 18-month Extension
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started77108
Completed66108
Not completed1100
Withdrew: Investigator decision0100
Withdrew: Subject discontinued due to needlephobia1000

Outcome measures

PrimaryOverall Summary of Adverse Events During Initial 6-Month Period

A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. Serious adverse event (SAE).

Time frame:
Up to Month 6 ± 7 Days
Reported as:
Count of participants · Participants
Overall Summary of Adverse Events During Initial 6-Month Period
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
Subjects with at Least 1 Reported TEAE88109
Subjects Least Reported Study Drug-Related TEAE7899
Subjects with at Least 1 Reported SAE0000
Subjects Least Reported Study Drug-Related SAE0000
Subjects Who Died0000
PrimaryOverall Summary of Adverse Events During Entire Study Period

A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. TEAE - Treatment-emergent adverse event. SAE - Serious adverse event.

Time frame:
Up to Month 25 ± 7 Days
Reported as:
Count of participants · Participants
Overall Summary of Adverse Events During Entire Study Period
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
Subjects with at Least 1 Reported TEAE88109
Subjects Least Reported Study Drug-Related TEAE7899
Subjects with at Least 1 Reported SAE1011
Subjects Least Reported Study Drug-Related SAE0000
Subjects Who Died0000
SecondaryChange From Baseline in Annualized Growth Velocity (AGV) During Initial 6-Month

Annualized Growth Velocity at Day 183 is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.

Time frame:
At 6 month (Day 183)
Reported as:
Mean · cm/year
Change From Baseline in Annualized Growth Velocity (AGV) During Initial 6-Month
cm/yearCohort 1Cohort 2Cohort 3Cohort 4
Baseline3.755 ± 1.10942.891 ± 1.39204.044 ± 2.27514.492 ± 1.1889
Change from Baseline to Day 183-0.371 ± 1.59201.276 ± 1.43872.014 ± 1.99902.085 ± 2.1375
SecondaryChange From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 3 and 4

Annualized Growth Velocity at Day 183 visit is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.

Time frame:
At month 24
Reported as:
Mean · cm/year
Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 3 and 4
cm/yearCohort 3Cohort 4
Baseline4.044 ± 2.27514.492 ± 1.1889
Change from Baseline to Month 241.744 ± 1.79741.538 ± 1.3387
SecondaryChange From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 1 and 2 Switchers

Annualized Growth Velocity at 1st visit with \>= 12 months on 15ug/kg is assessed on standing height as ((Height at 1st Visit with \>= 12 Months on 15 μg/kg - Height at 1st Visit on 15 μg/kg)/(Date of the 1st Visit with \>= 12 months on 15 μg/kg - Date of at 1st Visit on 15 μg/kg)) x 365.25.

Time frame:
At month 24
Reported as:
Mean · cm/year
Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 1 and 2 Switchers
cm/yearCohort 1Cohort 2
Baseline3.629 ± 1.15863.510 ± 0.8327
Change from Baseline at >=12 Months on 15μg/kg1.846 ± 2.14662.245 ± 0.9176
SecondaryChange From Baseline in Height Z-Scores Using Centers for Disease Control and Prevention (CDC) Reference Standard During Initial 6-Months

Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 Standard Deviation Scores (SDs) indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).

Time frame:
At month 6 (Day 183)
Reported as:
Mean · z score
Change From Baseline in Height Z-Scores Using Centers for Disease Control and Prevention (CDC) Reference Standard During Initial 6-Months
z scoreCohort 1Cohort 2Cohort 3Cohort 4
Baseline-6.056 ± 0.6331-5.145 ± 0.8530-4.613 ± 1.1355-5.193 ± 0.7486
Change from Baseline to Day 183-0.008 ± 0.17880.078 ± 0.14400.229 ± 0.15050.265 ± 0.1869
SecondaryChange From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 3 and 4

Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 SDs indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).

Time frame:
At month 24
Reported as:
Mean · z score
Change From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 3 and 4
z scoreCohort 3Cohort 4
Baseline-4.613 ± 1.1355-5.193 ± 0.7486
Change from Baseline to Month 240.788 ± 0.28420.896 ± 0.3010
SecondaryChange From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 1 and 2 Switchers

Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 SDs indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).

Time frame:
At month 24
Reported as:
Mean · z score
Change From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 1 and 2 Switchers
z scoreCohort 1Cohort 2
Baseline-6.064 ± 0.6932-4.912 ± 0.7708
Change from Baseline to >=12 Months on 15ug/kg0.520 ± 0.29500.259 ± 0.1887
SecondaryChange From Baseline in Upper to Lower Body Ratios During Initial 6-Months

The Upper to Lower Body ratio prior to treatment, at baseline, and through 6 months is assessed on Sitting Height / (Standing Height - Sitting Height)

Time frame:
At month 6 (Day 183)
Reported as:
Mean · Ratio
Change From Baseline in Upper to Lower Body Ratios During Initial 6-Months
RatioCohort 1Cohort 2Cohort 3Cohort 4
Baseline2.094 ± 0.09842.027 ± 0.17931.911 ± 0.22861.962 ± 0.1822
Change from Baseline to Day 183-0.021 ± 0.06260.003 ± 0.0510-0.024 ± 0.0369-0.030 ± 0.0811
SecondaryChange From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 3 and 4

The Upper to Lower Body ratio prior to treatment, at baseline, and through 24 months is assessed on Sitting Height / (Standing Height - Sitting Height)

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 3 and 4
ratioCohort 3Cohort 4
Baseline1.911 ± 0.22861.962 ± 0.1822
Change from Baseline to Month 24-0.067 ± 0.0451-0.121 ± 0.1058
SecondaryChange From Baseline in Upper Arm Length to Lower Arm (Forearm) Length Ratio During Initial 6-Months

The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 6 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.

Time frame:
At month 6 (Day 183)
Reported as:
Mean · ratio
Change From Baseline in Upper Arm Length to Lower Arm (Forearm) Length Ratio During Initial 6-Months
ratioCohort 1Cohort 2Cohort 3Cohort 4
Baseline1.130 ± 0.11681.143 ± 0.09241.130 ± 0.11901.106 ± 0.0816
Change from Baseline to Day 183-0.019 ± 0.06230.001 ± 0.0521-0.048 ± 0.10020.003 ± 0.0869
SecondaryChange From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 3 and 4

The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 24 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 3 and 4
ratioCohort 3Cohort 4
Baseline1.130 ± 0.11901.106 ± 0.0816
Change from Baseline to Month 240.037 ± 0.0673-0.027 ± 0.0504
SecondaryChange From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 1 and 2 Switchers

The Upper to Lower Body ratio prior to treatment, at baseline, and through 24 months is assessed on Sitting Height / (Standing Height - Sitting Height)

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 1 and 2 Switchers
ratioCohort 1Cohort 2
Baseline2.119 ± 0.08122.053 ± 0.1746
Change from Baseline to >=12 Months on 15ug/kg-0.078 ± 0.0452-0.078 ± 0.1271
SecondaryChange From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers

The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 24 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers
ratioCohort 1Cohort 2
Baseline1.131 ± 0.12801.114 ± 0.0520
Change from Baseline to >=12 Months on 15ug/kg0.009 ± 0.0056-0.004 ± 0.1181
SecondaryChange From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Initial 6-months

The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 6 months is assessed on Upper Leg Length (Thigh) / Knee to Heel Length.

Time frame:
At month 6 (Day 183)
Reported as:
Mean · ratio
Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Initial 6-months
ratioCohort 1Cohort 2Cohort 3Cohort 4
Baseline0.672 ± 0.06000.662 ± 0.05850.687 ± 0.02680.691 ± 0.0847
Change from Baseline to Day 183-0.002 ± 0.0401-0.006 ± 0.04620.007 ± 0.0411-0.006 ± 0.0810
SecondaryChange From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 3 and 4

The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh) / Knee to Heel Length.

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 3 and 4
ratioCohort 3Cohort 4
Baseline0.687 ± 0.02680.691 ± 0.0847
Change from Baseline to Month 240.010 ± 0.0503-0.033 ± 0.1065
SecondaryChange From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers

The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh) / Knee to Heel Length.

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers
ratioCohort 1Cohort 2
Baseline0.659 ± 0.05410.673 ± 0.0579
Change from Baseline to >=12 Months on 15ug/kg0.002 ± 0.02280.006 ± 0.0618
SecondaryChange From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Initial 6-months

The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 6 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.

Time frame:
At month 6 (Day 183)
Reported as:
Mean · ratio
Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Initial 6-months
ratioCohort 1Cohort 2Cohort 3Cohort 4
Baseline1.089 ± 0.10671.074 ± 0.13501.107 ± 0.06071.061 ± 0.1341
Change from Baseline to Day 1830.001 ± 0.07740.007 ± 0.08630.034 ± 0.10480.015 ± 0.1571
SecondaryChange From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 3 and 4

The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 3 and 4
ratioCohort 3Cohort 4
Baseline1.107 ± 0.06071.061 ± 0.1341
Change from Baseline to Month 240.014 ± 0.0888-0.012 ± 0.1477
SecondaryChange From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers

The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers
ratioCohort 1Cohort 2
Baseline1.080 ± 0.11391.100 ± 0.1447
Change from Baseline to >=12 Months on 15ug/kg-0.020 ± 0.02970.018 ± 0.1602
SecondaryChange From Baseline in Arm Span to Height Ratio During Initial 6-months

The Arm Span to Height Ratio prior to treatment, at baseline, and through 6 months is assessed by Arm Span / Standing Height.

Time frame:
At month 6 (Day 183)
Reported as:
Mean · ratio
Change From Baseline in Arm Span to Height Ratio During Initial 6-months
ratioCohort 1Cohort 2Cohort 3Cohort 4
Baseline0.901 ± 0.01890.889 ± 0.09060.913 ± 0.01230.893 ± 0.0284
Change from Baseline to Day 1830.012 ± 0.0111-0.005 ± 0.00790.007 ± 0.00630.001 ± 0.0143
SecondaryChange From Baseline in Arm Span to Height Ratio During Entire Study Period - Cohort 3 and 4

The Arm Span to Height Ratio prior to treatment, at baseline, and through 24 months is assessed by Arm Span / Standing Height.

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Arm Span to Height Ratio During Entire Study Period - Cohort 3 and 4
ratioCohort 3Cohort 4
Baseline0.911 ± 0.01190.900 ± 0.0315
Change from Baseline to Month 240.000 ± 0.0123-0.006 ± 0.0290
SecondaryChange From Baseline in Arm Span to Height Ratio During Entire Study Period - Cohort 1 and 2 Switchers

The Arm Span to Height Ratio prior to treatment, at baseline, and through 24 months is assessed by Arm Span / Standing Height. Values are not available for participants in cohort 1 switchers for Change from Baseline to \>=12 Months on 15ug/kg.

Time frame:
At month 24
Reported as:
Mean · ratio
Change From Baseline in Arm Span to Height Ratio During Entire Study Period - Cohort 1 and 2 Switchers
ratioCohort 2
Baseline0.881 ± 0.0480
Change from Baseline to >=12 Months on 15ug/kg-0.014 ± 0.0179

Adverse events

Collected over Up to Month 25 ± 7 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial 6-Months Period 2.5 µg/kg.0/8 (0%)0/8 (0%)8/8 (100%)
Initial 6-Months Period 7.5 µg/kg.0/8 (0%)0/8 (0%)8/8 (100%)
Initial 6-Months Period 15 µg/kg.0/10 (0%)0/10 (0%)10/10 (100%)
Initial 6-Months Period 30 µg/kg.0/9 (0%)0/9 (0%)9/9 (100%)
Extension Period 2.5 µg/kg.0/7 (0%)1/7 (14.3%)7/7 (100%)
Extension Period 7.5 µg/kg.0/14 (0%)0/14 (0%)13/14 (92.9%)
Extension Period 15 µg/kg.0/22 (0%)1/22 (4.5%)22/22 (100%)
Extension Period 30 µg/kg.0/8 (0%)1/8 (12.5%)8/8 (100%)
Entire Study Period 2.5 µg/kg.0/8 (0%)1/8 (12.5%)8/8 (100%)
Entire Study Period 7.5 µg/kg.0/15 (0%)0/15 (0%)14/15 (93.3%)
Entire Study Period 15 µg/kg.0/22 (0%)1/22 (4.5%)22/22 (100%)
Entire Study Period 30 µg/kg.0/9 (0%)1/9 (11.1%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventInitial 6-Months Period 2.5 µg/kg.Initial 6-Months Period 7.5 µg/kg.Initial 6-Months Period 15 µg/kg.Initial 6-Months Period 30 µg/kg.Extension Period 2.5 µg/kg.Extension Period 7.5 µg/kg.Extension Period 15 µg/kg.Extension Period 30 µg/kg.Entire Study Period 2.5 µg/kg.Entire Study Period 7.5 µg/kg.Entire Study Period 15 µg/kg.Entire Study Period 30 µg/kg.
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/80/80/100/91/70/140/220/81/80/150/220/9
Thyroglossal cystCongenital, familial and genetic disorders0/80/80/100/90/70/140/221/80/80/150/221/9
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders0/80/80/100/90/70/141/220/80/80/151/220/9
Most frequent other events
Showing 10 of 163
Most frequent other events
EventInitial 6-Months Period 2.5 µg/kg.Initial 6-Months Period 7.5 µg/kg.Initial 6-Months Period 15 µg/kg.Initial 6-Months Period 30 µg/kg.Extension Period 2.5 µg/kg.Extension Period 7.5 µg/kg.Extension Period 15 µg/kg.Extension Period 30 µg/kg.Entire Study Period 2.5 µg/kg.Entire Study Period 7.5 µg/kg.Entire Study Period 15 µg/kg.Entire Study Period 30 µg/kg.
Injection site reactionGeneral disorders2/86/88/109/92/75/1415/226/82/88/1517/229/9
Injection site erythemaGeneral disorders4/87/89/109/91/75/1411/226/84/87/1514/229/9
Injection site swellingGeneral disorders4/82/84/102/90/70/148/221/84/82/158/222/9
PyrexiaGeneral disorders4/81/83/102/90/71/145/221/84/82/157/222/9
CoughRespiratory, thoracic and mediastinal disorders4/80/82/104/90/72/144/221/84/82/156/224/9
HeadacheNervous system disorders4/82/82/103/91/71/145/220/84/83/156/223/9
Pain in extremityMusculoskeletal and connective tissue disorders1/80/80/101/90/70/142/224/81/80/152/224/9
HypotensionVascular disorders3/84/84/102/91/71/143/222/84/85/157/222/9
Injection site urticariaGeneral disorders1/81/82/103/91/71/143/221/81/82/153/224/9
NasopharyngitisInfections and infestations1/83/83/101/90/71/144/222/81/83/157/222/9

Baseline characteristics

Safety Analysis Population consists of all subjects who received at least one dose of study treatment and were used for safety analysis in the initial 6-month period and entire study period.

Age, Continuous
Age, Continuous(yrs)Cohort 1Cohort 2Cohort 3Cohort 4Total
Mean7.3 ± 1.588.3 ± 2.198.0 ± 1.636.9 ± 1.177.6 ± 1.68
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Female536519
Male354416
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Hispanic or Latino00112
Not Hispanic or Latino889732
Unknown or Not Reported00011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
White765624
Asian01337
Black or African American10102
Other01102
08

Study locations

9 sites
  • Children's Hospital & Research Center Oakland
    Oakland, California 94609, United States
  • Harbor - UCLA Medical Center
    Torrance, California 90509, United States
  • Ann and Robert H. Lurie Childrens Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Johns Hopkins McKusick - Institute of Genetic Medicine
    Baltimore, Maryland 21287, United States
  • Vanderbilt University
    Nashville, Tennessee 37232-2578, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Murdoch Children's Research Institute
    Parkville, Victoria 3052, Australia
  • Institut Necker
    Paris, 75015, France
  • Guys & St. Thomas NHS Foundation Trust Evelina Hospital
    London, SE1 9RT, United Kingdom
09

References and documents

Publications

  • Chan ML, Qi Y, Larimore K, Cherukuri A, Seid L, Jayaram K, Jeha G, Fisheleva E, Day J, Huntsman-Labed A, Savarirayan R, Irving M, Bacino CA, Hoover-Fong J, Ozono K, Mohnike K, Wilcox WR, Horton WA, Henshaw J. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. Clin Pharmacokinet. 2022 Feb;61(2):263-280. doi: 10.1007/s40262-021-01059-1. Epub 2021 Aug 25. PubMed 34431071 ↗
  • Savarirayan R, Irving M, Bacino CA, Bostwick B, Charrow J, Cormier-Daire V, Le Quan Sang KH, Dickson P, Harmatz P, Phillips J, Owen N, Cherukuri A, Jayaram K, Jeha GS, Larimore K, Chan ML, Huntsman Labed A, Day J, Hoover-Fong J. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. N Engl J Med. 2019 Jul 4;381(1):25-35. doi: 10.1056/NEJMoa1813446. Epub 2019 Jun 18. PubMed 31269546 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Oct 2017, 44 months.

Results were first posted in Jan 2021, 3 years 3 months after primary completion. A results delay was requested in Sep 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2013
First posted
Feb 5, 2014
StartActual
Jan 13, 2014
Primary completionActual
Oct 2, 2017
CompletionActual
Oct 2, 2017
Results delay requested
Sep 19, 2018
Results first posted
Jan 15, 2021
Last update
Jan 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02055157
Responsible party
Sponsor
First posted
Feb 5, 2014
Start date
Jan 13, 2014
Primary completion
Oct 2, 2017
Completion
Oct 2, 2017
Results posted
Jan 15, 2021
Last update
Jan 15, 2021

Study contacts

Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vosoritide

Start the discussion